Literature DB >> 11248330

Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias.

W K Hofmann1, C W Miller, K Tsukasaki, S Tavor, T Ikezoe, D Hoelzer, S Takeuchi, H P Koeffler.   

Abstract

Checkpoint genes code for a family of proteins which sense DNA damage in eukaryotic cells. They play an important role in the control of the cell cycle. The human CHK2 is a homolog of the yeast G(2) checkpoint kinases known as CDS1 and RAD53. The CHK2 may be a tumor suppressor gene because it was found to be mutated in some individuals with the Li-Fraumeni syndrome. These cases had a normal, non-mutated p53 gene. We performed a mutational analysis of the CHK2 gene using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) in 41 bone marrow samples from individuals with myelodysplastic syndrome (MDS) and 41 samples of acute myeloid leukemias (AML). We found a novel G to C transversion resulting in a change from Ala to Gly at codon 507 of CHK2 in one MDS sample, but normal cells from this individual did not have the abnormality. In addition, we demonstrated a previously described polymorphism at codon 84 (A to G at nucleotide 252) of exon 1 of CHK2 in three of 41 MDS and three of 41 AML patients. The presence of a CHK2 mutation in MDS highlights the importance of alterations of cell cycle checkpoint genes in this disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248330     DOI: 10.1016/s0145-2126(00)00130-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

1.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

Review 2.  Important features of myelodysplastic syndrome.

Authors:  Wolf K Hofmann; H Phillip Koeffler
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Chk2 activation and phosphorylation-dependent oligomerization.

Authors:  Xingzhi Xu; Lyuben M Tsvetkov; David F Stern
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

4.  Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Authors:  Mieke Schutte; Sheila Seal; Rita Barfoot; Hanne Meijers-Heijboer; Marijke Wasielewski; D Gareth Evans; Diana Eccles; Carel Meijers; Frans Lohman; Jan Klijn; Ans van den Ouweland; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

Review 5.  Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.

Authors:  Ryan J Stubbins; Sophia Korotev; Lucy A Godley
Journal:  Curr Hematol Malig Rep       Date:  2022-06-08       Impact factor: 4.213

6.  Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.

Authors:  Sang Soo Kim; Liu Cao; Cuiling Li; Xiaoling Xu; L Julie Huber; Lewis A Chodosh; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

7.  The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN).

Authors:  Kathrin Scheckenbach; Galatia Papadopoulou; Thomas K Hoffmann; Adam Chaker; Henning Bier; Jörg Schipper; Vera Balz; Martin Wagenmann
Journal:  J Negat Results Biomed       Date:  2010-12-25

8.  The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis.

Authors:  L B Koppert; M Schutte; M Abbou; H W Tilanus; W N M Dinjens
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

9.  Analysis of CHK2 in vulval neoplasia.

Authors:  A Reddy; M Yuille; A Sullivan; C Repellin; A Bell; J A Tidy; D J Evans; P J Farrell; B Gusterson; M Gasco; T Crook
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

10.  Mutation analysis of the CHK2 gene in breast carcinoma and other cancers.

Authors:  Sigurdur Ingvarsson; Bjarnveig I Sigbjornsdottir; Chen Huiping; Sigridur H Hafsteinsdottir; Gisli Ragnarsson; Rosa B Barkardottir; Adalgeir Arason; Valgardur Egilsson; Jon T H Bergthorsson
Journal:  Breast Cancer Res       Date:  2002-03-20       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.